CytomX advancing PD-L1-targeting 'Probodies' with $70m in new cash
This article was originally published in Scrip
Executive Summary
Californian biotech CytomX has raised $70m in a series D financing in order to take its "Probody" therapeutic pipeline into clinical trials.